What is the current Genomic Biomarker market size?

The Genomic Biomarker market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Genomic Biomarker market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by advancements in technology.

What are the key drivers of the Genomic Biomarker market?

Key drivers include increasing demand for personalized medicine and growing investments in genomics research.

What are the major challenges facing the Genomic Biomarker market?

Challenges include high development costs, regulatory hurdles, and data analysis complexities.

Which regions are expected to lead the Genomic Biomarker market?

North America and Europe are expected to dominate the market due to strong research infrastructure.

Who are the top companies in the Genomic Biomarker market?

Top companies include Illumina, Thermo Fisher Scientific, and Qiagen, driving innovation and growth.

What future opportunities exist in the Genomic Biomarker market?

Future opportunities include emerging applications in precision medicine and increasing adoption in developing economies.

How is technology impacting the Genomic Biomarker market?

Advances in sequencing technologies and bioinformatics are transforming the market, enabling faster and more accurate analysis.

What is the current regulatory landscape for the Genomic Biomarker market?

The regulatory landscape is evolving, with ongoing efforts to standardize testing and validation procedures.

What is the future outlook for the Genomic Biomarker market?

The future outlook is promising, with expected growth driven by increasing demand for genomic-based diagnostics and therapeutics.

Genomic Biomarker Strategic Analysis & Growth Outlook 2033

Genomic Biomarker by Application (/> Hospitals, Diagnostic and research laboratories), by Type (/> Protein Marker, Nucleic Acid Marker, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Genomic Biomarker Market Size | CAGR 10.2 Forecast 2033

Genomic Biomarker Strategic Analysis & Growth Outlook 2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Genomic Biomarker Market Overview

The Genomic Biomarker market refers to the industry that focuses on the development and application of genomic biomarkers for various diseases and conditions. As the Genomic Biomarker market size is expected to grow significantly, driven by the increasing demand for personalized medicine and targeted therapies, the growth outlook and market forecast are crucial for industry players. The industry expansion is expected to be driven by advancements in technology, government initiatives, and the rising awareness about the importance of genomic biomarkers. According to recent estimates, the current Genomic Biomarker market size is approximately $4.8 billion. The market is expected to grow at a CAGR of 13.5% during the forecast period, driven by macro drivers such as increasing research and development activities, rising demand for precision medicine, and growing awareness about the importance of genomic biomarkers.

Loading chart…

The key forces shaping the Genomic Biomarker industry include technology shifts, such as the development of high-throughput sequencing technologies, regulations, such as the increasing need for regulatory approvals, and consumer behavior, such as the growing awareness about the importance of genomic biomarkers. The largest region in the Genomic Biomarker market is North America, while the fastest-growing region is Asia-Pacific. The market is expected to be driven by the increasing demand for personalized medicine and targeted therapies, and the growing awareness about the importance of genomic biomarkers. As the industry continues to evolve, it is crucial for players to stay ahead of the curve and adapt to the changing landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad; Beckman Coulter; Myriad Genetics; Thermo Fisher Scientific; Roche; QIAGEN; Epigenomics; Almac; Pfizer; Human Longevity; ValiRx; Personalis; Eagle Genomics; Empire Genomics; Agilent; Illumina
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Genomic Biomarker market is poised for significant growth, driven by advancements in technology and increasing demand for personalized medicine. The growth forecast for the Genomic Biomarker market size is expected to be substantial, with major players investing heavily in research and development.

Growth Drivers2 items

Advances in next-generation sequencing technologies have improved the speed and cost-effectiveness of genomic biomarker discovery, driving growth in the Genomic Biomarker market

Increasing demand for precision medicine has led to a surge in the adoption of genomic biomarkers, further fueling the growth forecast for the Genomic Biomarker market size

Restraints2 items

High development costs associated with genomic biomarker validation and regulatory approvals are restraining the growth of the Genomic Biomarker market

Limited reimbursement policies for genomic biomarker-based tests are hindering the widespread adoption of these tests, affecting the Genomic Biomarker market size

Opportunities2 items

The increasing availability of large-scale genomic data is creating new opportunities for the development of novel genomic biomarkers, driving growth in the Genomic Biomarker market

Growing collaborations between industry players and research institutions are accelerating the discovery and validation of genomic biomarkers, positively impacting the growth forecast for the Genomic Biomarker market size

Challenges2 items

The complexity of genomic data analysis and interpretation is a significant challenge in the Genomic Biomarker market, requiring advanced bioinformatics tools and expertise

Ensuring the standardization and quality control of genomic biomarker-based tests is crucial to maintaining consumer trust and confidence in the Genomic Biomarker market

Market Segmentation

Loading chart…

The Application segment in the Genomic Biomarker market refers to the various uses of genomic biomarkers in different fields, such as oncology, cardiovascular diseases, and neurological disorders. This segment contributes significantly to the overall Genomic Biomarker market size, as it encompasses a wide range of applications, including diagnostic, prognostic, and therapeutic purposes. The Genomic Biomarker segmentation by application helps to identify the most promising areas of growth and investment in the market.

The Type segment in the Genomic Biomarker market is categorized into subtypes, including germline biomarkers and somatic biomarkers. This segmentation is crucial in understanding the market taxonomy and the various types of biomarkers used in different applications. The type segment contributes to the overall market size by providing insights into the prevalence and usage of different biomarker types, enabling stakeholders to make informed decisions about investments and research.

Genomic Biomarker Segmentation Breakdown7 items

Application

/> Hospitals

Diagnostic and research laboratories

Type

/> Protein Marker

Nucleic Acid Marker

Other

Regional Insights

Loading chart…

The Genomic Biomarker market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be the Asia Pacific, driven by increasing adoption of genomic biomarkers in clinical trials and rising investments in genomics research.

Key drivers for the North America region include established infrastructure, favorable policies, and a mature ecosystem. In Europe, drivers include increased funding for genomics research, growing demand for personalized medicine, and stricter regulatory policies. The Asia Pacific region is driven by rapidly expanding economies, increasing demographics with a growing middle class, and government initiatives to promote genomics research.

Latin America and Middle East & Africa are expected to experience moderate regional forecast growth, driven by improving infrastructure, growing awareness of genomic biomarkers, and rising investments in healthcare. However, these regions face challenges such as limited access to genomic testing and lack of standardization in regulatory policies.

Competitive Landscape

The Genomic Biomarker market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The Genomic Biomarker competitive landscape is driven by the need for companies to differentiate themselves through innovative products and services. Key players are focusing on strategic levers like pricing, partnerships, and product launches to gain a competitive edge.

Companies in the Genomic Biomarker market are adopting various strategies to stay competitive, including M&A, partnerships, and R&D investments. However, they face challenges like margin pressure, compliance costs, and commoditization. To differentiate themselves, companies are focusing on technology, service models, channel strength, customization, and cost advantages. The following companies are pursuing specific strategic focuses:

Bio-Rad: regional expansion

Beckman Coulter: vertical integration

Myriad Genetics: premium pricing

Thermo Fisher Scientific: OEM tie-ups

Roche: innovation pipeline

QIAGEN: local manufacturing

Key Genomic Biomarker Companies16 items

Bio-Rad

Beckman Coulter

Myriad Genetics

Thermo Fisher Scientific

Roche

QIAGEN

Epigenomics

Almac

Pfizer

Human Longevity

ValiRx

Personalis

Eagle Genomics

Empire Genomics

Agilent

Illumina

Market Ecosystem

The Genomic Biomarker ecosystem encompasses a complex network of participants, spanning upstream technology providers to downstream end users. Value is created and captured as genomic data is generated, analyzed, and interpreted, with each participant playing a distinct role in the value chain analysis. The ecosystem can be broadly categorized into three segments: upstream technology providers and suppliers, midstream integrators and channels, and downstream end users.

Technology providers — develop genomic analysis platforms

Raw material/component suppliers — provide reagents and equipment

System integrators / EPCs — integrate genomic data analysis systems

Distributors / channel partners — supply genomic analysis products

Service providers / after-sales — offer data analysis and interpretation services

End users / buyers — utilize genomic biomarkers for research and diagnostics

Regulators/standards bodies — establish guidelines and standards for genomic data analysis

In the Genomic Biomarker ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the adoption of genomic biomarkers through stringent guidelines and approvals. Dependency risks arise from input constraints, such as the availability of high-quality genomic data, and standards, which can create bottlenecks in the ecosystem. Switching costs and partnerships between technology providers and end users can also impact the ecosystem, with interoperability requirements playing a crucial role in facilitating the flow of genomic data. Furthermore, regional differences in the ecosystem may arise due to varying regulatory frameworks and standards, affecting the adoption and utilization of genomic biomarkers.

Recent Industry Insights

The Genomic Biomarker industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in technology and increasing demand for personalized medicine. Recent partnerships between key players have focused on accelerating the discovery and development of novel biomarkers, while mergers and acquisitions have led to the consolidation of resources and expertise.

Notable developments include product launches and technology upgrades that have improved the accuracy and efficiency of biomarker detection. Additionally, regulatory changes have created new opportunities for the adoption of genomic biomarkers in clinical practice. The industry has also seen significant funding rounds and expansions, further fueling innovation and growth in the Genomic Biomarker market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Genomic Biomarker market outlook. The market exhibits high attractiveness due to increasing demand for precision medicine and personalized healthcare. The competitive intensity is moderate, with key players focusing on innovation and strategic partnerships. The long-term outlook is promising, driven by advancements in genomic sequencing technologies and growing applications in oncology and rare diseases.

The innovation landscape is rapidly evolving, with emerging trends such as liquid biopsies and artificial intelligence in biomarker discovery. However, the demand-supply balance is a key concern, with a shortage of skilled professionals and high infrastructure costs. Key risk factors include regulatory uncertainties and intellectual property issues. Overall, the Genomic Biomarker market is poised for significant growth, offering opportunities for investors, researchers, and healthcare providers.

11 items

1. Executive Summary

2. Genomic Biomarker Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Genomic Biomarker Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Genomic Biomarker Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Hospitals

6.1.2. Diagnostic and research laboratories

6.2. Global Genomic Biomarker Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> Protein Marker

6.2.2. Nucleic Acid Marker

6.2.3. Other

6.3. Global Genomic Biomarker Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Genomic Biomarker Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Genomic Biomarker Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Genomic Biomarker Market Competition by Key Manufacturers

8.1. Global Genomic Biomarker Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Genomic Biomarker: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Beckman Coulter

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Myriad Genetics

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. QIAGEN

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Epigenomics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Almac

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pfizer

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Human Longevity

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. ValiRx

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Personalis

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Eagle Genomics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Empire Genomics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Agilent

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Illumina

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Genomic Biomarker Market

Figure 4: Global Genomic Biomarker Market: Drivers

Figure 5: Global Genomic Biomarker Market: Challenges

Figure 6: Global Genomic Biomarker Market: Trends

Figure 7: Global Genomic Biomarker Market: Opportunity

Figure 8: Global Genomic Biomarker Market: Restraint

Figure 9: Global Genomic Biomarker Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Genomic Biomarker Market Value (USD Million) By Region

Figure 15: Global Genomic Biomarker Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Genomic Biomarker Market Value (USD Million) By Region

Figure 23: Global Genomic Biomarker Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

85 items

Table 1: Market Segmentation Analysis

Table 2: Global Genomic Biomarker Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Genomic Biomarker Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Genomic Biomarker Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Genomic Biomarker Market Value (USD Million) By Region

Table 10: Global Genomic Biomarker Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Genomic Biomarker Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Genomic Biomarker Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Genomic Biomarker Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Basic Information And Sales Area

Table 31: Bio-Rad. Products Portfolio

Table 32: Beckman Coulter Basic Information And Sales Area

Table 33: Beckman Coulter. Products Portfolio

Table 34: Myriad Genetics Basic Information And Sales Area

Table 35: Myriad Genetics. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: QIAGEN Basic Information And Sales Area

Table 41: QIAGEN. Products Portfolio

Table 42: Epigenomics Basic Information And Sales Area

Table 43: Epigenomics. Products Portfolio

Table 44: Almac Basic Information And Sales Area

Table 45: Almac. Products Portfolio

Table 46: Pfizer Basic Information And Sales Area

Table 47: Pfizer. Products Portfolio

Table 48: Human Longevity Basic Information And Sales Area

Table 49: Human Longevity. Products Portfolio

Table 50: ValiRx Basic Information And Sales Area

Table 51: ValiRx. Products Portfolio

Table 52: Personalis Basic Information And Sales Area

Table 53: Personalis. Products Portfolio

Table 54: Eagle Genomics Basic Information And Sales Area

Table 55: Eagle Genomics. Products Portfolio

Table 56: Empire Genomics Basic Information And Sales Area

Table 57: Empire Genomics. Products Portfolio

Table 58: Agilent Basic Information And Sales Area

Table 59: Agilent. Products Portfolio

Table 60: Illumina Basic Information And Sales Area

Table 61: Illumina. Products Portfolio

Table 62: Global Market Value (USD Million) (2025-2032) By Application

Table 63: Global Market Share (%) By Application (2032)

Table 64: Global Market Value (USD Million) (2025-2032) By Type

Table 65: Global Market Share (%) By Type (2032)

Table 66: Global Genomic Biomarker Market Value (USD Million) By Region

Table 67: Global Genomic Biomarker Market Share (%) By Region (2025-2032)

Table 68: North America Market Value (USD Million) (2025-2032) By Country

Table 69: North America Market Value (USD Million) (2025-2032) By Application

Table 70: North America Market Value (USD Million) (2025-2032) By Type

Table 71: Europe Market Value (USD Million) (2025-2032) By Country

Table 72: Europe Market Value (USD Million) (2025-2032) By Application

Table 73: Europe Market Value (USD Million) (2025-2032) By Type

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 77: South America Market Value (USD Million) (2025-2032) By Country

Table 78: South America Market Value (USD Million) (2025-2032) By Application

Table 79: South America Market Value (USD Million) (2025-2032) By Type

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 83: Research Programs/Design For This Report

Table 84: Key Data Information From Secondary Sources

Table 85: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Genomic Biomarker Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	26.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad; Beckman Coulter; Myriad Genetics; Thermo Fisher Scientific; Roche; QIAGEN; Epigenomics; Almac; Pfizer; Human Longevity; ValiRx; Personalis; Eagle Genomics; Empire Genomics; Agilent; Illumina
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options